Skip to Main Content

Paper Details

A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer.
Cancer Res Commun
3
2023
CTL antigen-4, HER2, HER2-negative Breast Cancer, HER2-negative breast cancer, T, T-VEC, breast cancer, hypotension, hypothyroidism, immune cell, patient, patients, programmed death receptor 1, type 1 diabetes mellitus
Author NameAffiliation
Antoni RibasUniversity of California los angeles
Antoni RibasJonsson Comprehensive Cancer Center, University of California los angeles
Antoni RibasUniversity of California los angeles
Antoni RibasUniversity of California los angeles
Antoni RibasUniversity of California los angeles
Antoni RibasUniversity of California los angeles
Antoni RibasJonsson Comprehensive Cancer Center, University of California los angeles
Antoni RibasUniversity of California los angeles
Antoni RibasUniversity of California los angeles
Antoni RibasUniversity of California los angeles
  • 1 - 10

Datasets

Release 1.2